Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello
Welcome,         Profile    Billing    Logout  
 77 Trials 
811 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Patti, Caterina
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
RAFTING, NCT04866654 / 2020-002382-33: Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Recruiting
2
160
Europe
Nivolumab 10 MG/ML
Medical University of Gdansk, Medical Research Agency
Hodgkin Lymphoma
09/22
07/26
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
LH_BIO, NCT06822855: Changing Paragidms in the Prognostic Assessment of Hodgkin Lymphoma

Recruiting
N/A
755
Europe
Azienda Unità Sanitaria Locale Reggio Emilia
Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
12/26
12/26
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting
N/A
321
Europe
Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
01/23
10/25
CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting
N/A
954
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi
Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19
09/24
09/24
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
NCT06774677: Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management

Recruiting
N/A
50
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia (HCL)
08/26
08/26
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Zinzani, Pier Luigi
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
LORELY, NCT06918912 / 2022-001147-24: Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Recruiting
2
50
Europe
Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)
Istituto Clinico Humanitas
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma
03/25
06/27
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Recruiting
2
115
Europe, US, RoW
PTX-100
Prescient Therapeutics, Ltd.
CTCL
01/28
06/28
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
05/26
05/32
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed
1
106
Europe, US
Tinostamustine, EDO-S101
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
05/23
11/23
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Active, not recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
DLBCL - Diffuse Large B Cell Lymphoma
12/25
12/25
VAX4FRAIL, NCT04848493: National Project on Vaccines, COVID-19 and Frail Patients

Recruiting
N/A
1300
Europe
COVID-19 vaccines
Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna
COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases
07/21
04/22
LYMPH-OS, NCT06814925: Italian Study of Patients with Lymphoma

Recruiting
N/A
1500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma
08/26
08/26
RETRO-LYMPH, NCT06781437: Retrospective Observational Study of Italian Cohort of Lymphoma Patients

Recruiting
N/A
5500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoproliferative Syndrome, Autoimmune, Lymphoma
12/27
12/27
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context

Recruiting
N/A
50
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Primary Mediastinal B Cell Lymphoma
12/25
12/25
PIXBRIDGE, NCT06760936: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients

Active, not recruiting
N/A
15
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma (DLBCL)
12/25
12/25
MEPI-AGE, NCT06761274: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Recruiting
N/A
200
Europe
peripheral blood sampling
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma in Remission
09/25
09/25
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
AMICO, NCT06814405: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management with Early Discharge of Patients with Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

Recruiting
N/A
100
Europe
Home patient management, Hospital patient management
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Haematological Malignancy
12/25
12/25
NCT03797170: Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
50
Europe
Gut microbiota samples
University of Bologna
Diffuse Large B Cell Lymphoma
07/23
12/23
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
N/A
170
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLBCL - Diffuse Large B Cell Lymphoma
02/24
04/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
HL-SIP, NCT06733987: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Recruiting
N/A
40
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma
02/27
02/27
CLIO, NCT06720701: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.

Not yet recruiting
N/A
125
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non-Hodgkin Lymphoma
12/26
12/26
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting
N/A
400
Europe
Fondazione Italiana Linfomi - ETS, Takeda
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
07/26
07/26
BRAF, NCT06781515: Assessment of Disease Burden in Hairy Cell Leukemia

Recruiting
N/A
45
Europe
Peripheral and BM blood sample
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia
11/25
11/25
FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
05/25
07/25
MarZoLyOss, NCT06806488: Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Recruiting
N/A
160
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone B Cell Lymphoma
10/25
10/25
Endemato, NCT06851702: Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients with Hematological Malignancies and Subjected to Treatment with Immune-checkpoint Inhibitors

Recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematological Malignancies
12/25
12/25
ACCELERATE, NCT02817997: International Registry for Patients With Castleman Disease

Recruiting
N/A
1000
US
University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA)
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
09/26
09/26
MicroCar, NCT05725720: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy

Recruiting
N/A
90
Europe
Gut microbiome analysis
University of Bologna, Associazione Italiana per la Ricerca sul Cancro, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma
07/27
12/27
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Sancho, Juan Manuel
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
Knopinska-Posluszny, Wanda
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated
3
246
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
11/24
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
Pennese, Elsa
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
N/A
350
Europe
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma
12/25
12/25
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting
N/A
190
Europe
acalabrutinib, Calquence
AstraZeneca, Yghea
Chronic Lymphocytic Leukemia
02/30
02/30
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
N/A
170
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLBCL - Diffuse Large B Cell Lymphoma
02/24
04/26
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Hou, Xiaohua
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule

Recruiting
4
480
RoW
Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Functional Dyspepsia, Postprandial Distress Syndrome
12/23
12/23
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Recruiting
3
408
RoW
Vedolizumab IV, Placebo
Takeda
Crohn's Disease
03/30
05/31
NCT06194188: A Phase 2 Clinical Study of CU-20401

Active, not recruiting
2
108
RoW
Subcutaneous injection of CU-20401, cu-20401
Cutia Therapeutics（Wuxi）Co.,Ltd
Efficacy and Safety
09/24
12/24
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Patti, Caterina
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Hourglass May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum
Mantle Cell Lymphoma
05/21
05/26
RENOIR, NCT02390869 / 2012-003392-18: Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients

Active, not recruiting
3
128
Europe
R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R)
Fondazione Italiana Linfomi - ETS
Lymphoma, Follicular
01/23
08/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi

Recruiting
3
190
Europe
Radiotherapy, Radiotherapy plus Obinutuzumab
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Follicular Lymphoma
04/31
04/31
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
RAFTING, NCT04866654 / 2020-002382-33: Radiation Free Chemotherapy for Early Hodgkin Lymphoma

Recruiting
2
160
Europe
Nivolumab 10 MG/ML
Medical University of Gdansk, Medical Research Agency
Hodgkin Lymphoma
09/22
07/26
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
49
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Fondazione Italiana Linfomi - ETS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
04/26
04/29
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
FIL_A-BEGEV, NCT05300282: Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients

Recruiting
1/2
122
Europe
Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Relapsed or Refractory Hodgkin's Lymphoma
04/27
04/30
LH_BIO, NCT06822855: Changing Paragidms in the Prognostic Assessment of Hodgkin Lymphoma

Recruiting
N/A
755
Europe
Azienda Unità Sanitaria Locale Reggio Emilia
Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
12/26
12/26
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting
N/A
321
Europe
Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
01/23
10/25
CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy.

Recruiting
N/A
954
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi
Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19
09/24
09/24
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial

Recruiting
N/A
654
Europe
EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
06/25
06/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
NCT06774677: Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management

Recruiting
N/A
50
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia (HCL)
08/26
08/26
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Low Grade Non-Hodgkin's Lymphoma, Adult
02/25
02/25
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
Zinzani, Pier Luigi
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
LORELY, NCT06918912 / 2022-001147-24: Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Recruiting
2
50
Europe
Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)
Istituto Clinico Humanitas
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma
03/25
06/27
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Recruiting
2
115
Europe, US, RoW
PTX-100
Prescient Therapeutics, Ltd.
CTCL
01/28
06/28
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
05/26
05/32
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
FIH, NCT04104776 / 2020-004952-14: A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
210
Europe, US, RoW
CPI-0209
Constellation Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma
12/25
03/26
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed
1
106
Europe, US
Tinostamustine, EDO-S101
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
05/23
11/23
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Active, not recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
DLBCL - Diffuse Large B Cell Lymphoma
12/25
12/25
VAX4FRAIL, NCT04848493: National Project on Vaccines, COVID-19 and Frail Patients

Recruiting
N/A
1300
Europe
COVID-19 vaccines
Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna
COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases
07/21
04/22
LYMPH-OS, NCT06814925: Italian Study of Patients with Lymphoma

Recruiting
N/A
1500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma
08/26
08/26
RETRO-LYMPH, NCT06781437: Retrospective Observational Study of Italian Cohort of Lymphoma Patients

Recruiting
N/A
5500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoproliferative Syndrome, Autoimmune, Lymphoma
12/27
12/27
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context

Recruiting
N/A
50
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Primary Mediastinal B Cell Lymphoma
12/25
12/25
PIXBRIDGE, NCT06760936: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients

Active, not recruiting
N/A
15
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma (DLBCL)
12/25
12/25
MEPI-AGE, NCT06761274: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Recruiting
N/A
200
Europe
peripheral blood sampling
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma in Remission
09/25
09/25
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
AMICO, NCT06814405: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management with Early Discharge of Patients with Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

Recruiting
N/A
100
Europe
Home patient management, Hospital patient management
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Haematological Malignancy
12/25
12/25
NCT03797170: Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
50
Europe
Gut microbiota samples
University of Bologna
Diffuse Large B Cell Lymphoma
07/23
12/23
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
N/A
170
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLBCL - Diffuse Large B Cell Lymphoma
02/24
04/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
HL-SIP, NCT06733987: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Recruiting
N/A
40
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma
02/27
02/27
CLIO, NCT06720701: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.

Not yet recruiting
N/A
125
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non-Hodgkin Lymphoma
12/26
12/26
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting
N/A
400
Europe
Fondazione Italiana Linfomi - ETS, Takeda
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
07/26
07/26
BRAF, NCT06781515: Assessment of Disease Burden in Hairy Cell Leukemia

Recruiting
N/A
45
Europe
Peripheral and BM blood sample
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia
11/25
11/25
FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
05/25
07/25
MarZoLyOss, NCT06806488: Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Recruiting
N/A
160
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone B Cell Lymphoma
10/25
10/25
Endemato, NCT06851702: Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients with Hematological Malignancies and Subjected to Treatment with Immune-checkpoint Inhibitors

Recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematological Malignancies
12/25
12/25
ACCELERATE, NCT02817997: International Registry for Patients With Castleman Disease

Recruiting
N/A
1000
US
University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA)
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
09/26
09/26
MicroCar, NCT05725720: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy

Recruiting
N/A
90
Europe
Gut microbiome analysis
University of Bologna, Associazione Italiana per la Ricerca sul Cancro, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma
07/27
12/27
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Sancho, Juan Manuel
TOPAZ-1, NCT04895241 / 2020-005775-12: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Checkmark Trial initiation of TOPAZ-1 trial in lupus
Jun 2021 - Jun 2021: Trial initiation of TOPAZ-1 trial in lupus
Recruiting
3
540
Europe, US, RoW
Litifilimab, BIIB059, Placebo
Biogen
Lupus Erythematosus, Systemic
09/26
03/27
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
05/25
04/27
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE)

Hourglass Oct 2024 - Dec 2024 : Data for SLE
Hourglass Jul 2024 - Sep 2024 : Data for CLE
Completed
2
456
Europe, Japan, US, RoW
Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Systemic Lupus Erythematosus
11/24
11/24
Knopinska-Posluszny, Wanda
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated
3
246
Europe, Canada, US, RoW
Tamibarotene, SY-1425, Placebo, Azacitidine
Syros Pharmaceuticals
Myelodysplastic Syndromes
11/24
11/24
LOTIS 5, NCT04384484 / 2020-000241-14: Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Checkmark Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Sep 2022 - Sep 2022: Safety run-in data from LOTIS-5 trial in combination with rituximab in r/r DLBCL at SOHO 2022
Hourglass Sep 2021 - Dec 2021 : Submission for r/r DLBCL
Hourglass Nov 2021 - Dec 2021 : From LOTIS 5 trial in combination with rituximab for DLBCL
Active, not recruiting
3
440
Europe, Canada, Japan, US, RoW
Loncastuximab Tesirine, Zynlonta, ADCT-402, Rituximab, Gemcitabine, Oxaliplatin
ADC Therapeutics S.A., ADC Therapeutics SA
Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
06/25
06/28
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
Pennese, Elsa
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
07/28
07/30
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/24
12/25
FIORELLA, NCT03495960 / 2016-003116-12: Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System

Completed
2
72
Europe
Rituximab, Methotrexate, Procarbazine, Lenalidomide, Radiotherapy, Temozolomide
International Extranodal Lymphoma Study Group (IELSG)
Primary Central Nervous System Lymphoma
12/24
12/24
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Withdrawn
2
150
Europe
R-DHAP, Pola-R-DHAP
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
01/29
01/29
PIMENTO, NCT04333524: FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role

Recruiting
N/A
350
Europe
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma
12/25
12/25
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting
N/A
190
Europe
acalabrutinib, Calquence
AstraZeneca, Yghea
Chronic Lymphocytic Leukemia
02/30
02/30
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study.

Recruiting
N/A
80
Europe
Fondazione Italiana Linfomi - ETS
Mantle Cell Lymphoma
03/25
03/25
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
N/A
170
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLBCL - Diffuse Large B Cell Lymphoma
02/24
04/26
NCT05819528: Primary Cardiac Lymphoma: Italian Multicenter Experience

Recruiting
N/A
43
Europe
Fondazione Italiana Linfomi - ETS
Primary Cardiac Lymphoma
04/26
06/26
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors

Recruiting
N/A
552
Europe
Lifestyles Implemented-Survivorship Care Plan (LS-SCP)
Fondazione Italiana Linfomi - ETS
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)
02/26
02/26
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice

Recruiting
N/A
1500
Europe
"novel" MAB (alone or in combination)
Fondazione Italiana Linfomi - ETS, Roche Pharma AG
Non-Hodgkin Lymphoma, B-cell
10/38
10/38
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Hou, Xiaohua
NCT03825692: International Clinical Study of Zhizhu Kuanzhong Capsule

Recruiting
4
480
RoW
Zhizhu Kuanzhong Capsule, ZZKZ capsule, Zhizhu Kuanzhong Placebo Capsule, placebo
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Functional Dyspepsia, Postprandial Distress Syndrome
12/23
12/23
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Completed
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
NCT05837897: A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease

Recruiting
3
408
RoW
Vedolizumab IV, Placebo
Takeda
Crohn's Disease
03/30
05/31
NCT06194188: A Phase 2 Clinical Study of CU-20401

Active, not recruiting
2
108
RoW
Subcutaneous injection of CU-20401, cu-20401
Cutia Therapeutics（Wuxi）Co.,Ltd
Efficacy and Safety
09/24
12/24
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
 

Download Options